{"id":1198,"slug":"自体脂肪移植在监管上算什么-国内和国外的管理一样吗","question":"自体脂肪移植在监管上算什么？国内和国外的管理一样吗？","intent":"informational","language":"zh","url":"https://worldwiki.io/q/自体脂肪移植在监管上算什么-国内和国外的管理一样吗","entity":{"slug":"facial-fat-grafting","name":"Facial Fat Grafting","url":"https://worldwiki.io/entity/facial-fat-grafting"},"answer":{"short_answer":"本条目所依据的资料只记录了美国的一条规定：在同一次手术中从同一个人身上取出并回植到同一个人身上的组织，可豁免 21 CFR Part 1271 的人体组织机构管理要求（21 CFR 1271.15(b)）。这只针对「同一人、同一次手术」的自体脂肪，不能推广到经过细胞培养、扩增等额外处理的产品。资料中没有中国或韩国的相应条文，读者不应据此判断国内外管理宽严，应向当地监管部门或机构索取依据。","detailed_answer":"<p><strong>已核实：</strong>美国 21 CFR 1271.15(b) 规定，组织若在同一次外科手术中从同一个体取出并回植入该个体，可豁免 21 CFR Part 1271 的相关要求[4]。</p><p><strong>未涵盖（本条目无法回答）：</strong>中国对医疗美容机构与自体脂肪移植手术分级的规定、韩国的相应制度，以及两地对添加细胞类操作的审批要求。这些条文不在本条目引用的资料范围内。</p><p><strong>相关提示：</strong>细胞辅助脂肪移植的疗效证据被系统评价判定为不足[6]，面向患者的干细胞资料也指出美容类干细胞效果多数未经证实[7]；当一个项目宣称「已获批」时，应要求出示具体的批准文件编号并向监管部门核对。</p>","format":"paragraph","confidence":55,"verified_at":null,"updated_at":"2026-09-20 17:11:10"},"sources":[{"id":267,"title":"21 CFR § 1271.15 – Are there any exceptions from the requirements of this part?","url":"https://www.law.cornell.edu/cfr/text/21/1271.15","publisher":"Legal Information Institute, Cornell Law School (reproducing the US Code of Federal Regulations)","type":"academic","accessed_at":"2026-09-19 18:00:33"},{"id":23,"title":"Cell-Assisted Lipotransfer: A Systematic Review of its Efficacy","url":"https://pubmed.ncbi.nlm.nih.gov/37608190/","publisher":"Aesthetic Plastic Surgery (2024)","type":"academic","accessed_at":"2026-09-19 18:01:02"},{"id":15,"title":"About Stem Cells — patient resource","url":"https://www.aboutstemcells.org/","publisher":"International Society for Stem Cell Research","type":"organization","accessed_at":"2026-09-19 18:01:05"}],"published_at":"2026-09-20 08:11:10"}